IRIS
TOMELLERI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.566
NA - Nord America 2.112
AS - Asia 1.682
SA - Sud America 288
Continente sconosciuto - Info sul continente non disponibili 177
AF - Africa 31
OC - Oceania 3
Totale 6.859
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.940
RU - Federazione Russa 1.218
SG - Singapore 557
CN - Cina 537
IT - Italia 477
RO - Romania 269
BR - Brasile 238
HK - Hong Kong 208
SE - Svezia 170
VN - Vietnam 140
DE - Germania 123
CA - Canada 93
FR - Francia 83
BD - Bangladesh 71
GB - Regno Unito 71
FI - Finlandia 40
IN - India 33
JP - Giappone 25
PH - Filippine 25
AR - Argentina 23
PL - Polonia 22
MX - Messico 21
NL - Olanda 21
ES - Italia 20
AT - Austria 14
CR - Costa Rica 11
ID - Indonesia 11
TR - Turchia 11
ZA - Sudafrica 11
MY - Malesia 9
GT - Guatemala 8
LT - Lituania 8
AE - Emirati Arabi Uniti 7
CO - Colombia 7
EG - Egitto 7
IQ - Iraq 7
JM - Giamaica 7
EC - Ecuador 6
HN - Honduras 6
UA - Ucraina 6
VE - Venezuela 6
IE - Irlanda 5
MK - Macedonia 5
NI - Nicaragua 5
NP - Nepal 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
IR - Iran 4
PR - Porto Rico 4
TT - Trinidad e Tobago 4
XK - ???statistics.table.value.countryCode.XK??? 4
AU - Australia 3
GP - Guadalupe 3
KE - Kenya 3
KR - Corea 3
KZ - Kazakistan 3
MA - Marocco 3
PY - Paraguay 3
AL - Albania 2
BE - Belgio 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
HR - Croazia 2
IL - Israele 2
PE - Perù 2
PK - Pakistan 2
TH - Thailandia 2
UY - Uruguay 2
VI - Stati Uniti Isole Vergini 2
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CL - Cile 1
CU - Cuba 1
CW - ???statistics.table.value.countryCode.CW??? 1
GE - Georgia 1
HT - Haiti 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LV - Lettonia 1
MN - Mongolia 1
PS - Palestinian Territory 1
QA - Qatar 1
SC - Seychelles 1
SN - Senegal 1
SV - El Salvador 1
TG - Togo 1
TN - Tunisia 1
TW - Taiwan 1
Totale 6.687
Salva come PNG Salva come JPEG
Città #
Ashburn 316
Singapore 282
Moscow 241
Dallas 213
San Jose 212
Hong Kong 200
Milan 126
Shanghai 116
New York 81
Council Bluffs 78
Beijing 76
Hefei 63
Los Angeles 60
Munich 59
Lauterbourg 55
Ho Chi Minh City 54
Phoenix 53
Santa Clara 48
Boardman 38
São Paulo 36
Princeton 35
Lawrence 31
Rome 29
Hanoi 23
Helsinki 21
Orem 21
Atlanta 20
Montreal 20
Toronto 20
Nuremberg 19
Warsaw 19
Denver 18
Brooklyn 17
Tokyo 17
Chicago 16
Naples 14
London 13
Turku 13
Cesano Boscone 12
North Bergen 12
Boston 11
Chennai 10
Guangzhou 10
Johannesburg 10
Poplar 10
Stockholm 10
Frankfurt am Main 9
Makati City 9
Miano 9
Pune 9
Ankara 8
Bari 8
Florence 8
Manchester 8
Miami 8
Pietra Ligure 8
Rio de Janeiro 8
Seattle 8
Shenzhen 8
Verona 8
Mexico City 7
San José 7
Turin 7
Brescia 6
City of London 6
Da Nang 6
Falkenstein 6
Genoa 6
Guatemala City 6
Haiphong 6
Lappeenranta 6
San Francisco 6
Amsterdam 5
Ancona 5
Brasília 5
Buffalo 5
Dublin 5
Houston 5
Managua 5
Newark 5
Querétaro 5
Tashkent 5
The Dalles 5
Trento 5
Vittoria 5
Wolfhagen 5
Barnet 4
Cairo 4
Charlotte 4
Foshan 4
Goito 4
Jiaxing 4
Palermo 4
Paris 4
Philadelphia 4
Pisa 4
Pristina 4
Quezon City 4
Skopje 4
Sydney 4
Totale 3.175
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 402
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 195
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 192
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 192
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 165
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 157
A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM) 156
Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis 144
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 141
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 137
Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study 133
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFV600E mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman disease 131
Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort 128
Effectiveness and safety of infliximab dose escalation in patients with refractory Takayasu arteritis: A real-life experience from a monocentric cohort 126
Drug retention rates of biological agents in adult onset Still's disease 125
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 121
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 118
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 118
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 116
Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India 114
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 114
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 113
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 113
Giant cell arteritis: Update on clinical manifestations, diagnosis, and management 112
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 112
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 108
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 108
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 105
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 105
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 105
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients 104
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 101
VEXAS associated acute disseminated Encephalo-Myelitis (ADEM)-like syndrome: A case report and review of the literature 100
LONG-TERM PATHOPHYSIOLOGIC AND PROGNOSTIC EVALUATION OF DIFFERENT DISEASE SUBSETS IN GIANT CELL ARTERITIS 99
Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies 99
Clinically isolated aortitis successfully treated with methotrexate monotherapy 96
An enlightening scan 95
Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease 93
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 89
HETEROGENEITY OF CYTOPENIAS IN VEXAS SYNDROME: A SINGLE CENTRE EXPERIENCE 87
The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort 84
Clinical and dermoscopic description of accelerated nodulosis after tocilizumab treatment for an isolated aortitis with coronary involvement 82
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 81
Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study 76
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic 75
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use 74
Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement 74
Response to: 'Correspondence on Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: A monocentric survey' by Comarmond et al 71
Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: A monocentric survey 67
Failure of first anti-TNF agent in Takayasu’s arteritis: To switch or to swap? 64
Potential acceptance of COVID-19 vaccine in rheumatological patients: A monocentric comparative survey 64
Retention rates of different Janus kinase inhibitors in rheumatoid arthritis: experience from a large monocentric cohort 63
Efficacy of interleukin-1 blockade with anakinra in the management of post-COVID-19 steroid-dependent multisystem inflammatory syndrome: a case report 62
Large Vessel Vasculitis Affecting the Aorta and Its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature 61
Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis 61
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance 60
Multimodal chorioretinal imaging in erdheim-chester disease 59
One year later: The case of tocilizumab in COVID-19 58
Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series 58
Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply 55
Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease 54
Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients 54
The target on B cells in Systemic Sclerosis: a “midsummer dream” to extinguish inflammation and prevent early disease progression to fibrosis 54
Myocardial infarction in giant cell arteritis: It is all a matter of balance 53
Spontaneous coronary-artery dissection 47
Safety and effectiveness of the combination of 5-azacitidine and ruxolitinib in VEXAS syndrome: A single-centre experience 26
Real-life use of high-dose anakinra in patients with COVID-19 treated with remdesivir 22
Erythroid-stimulating agents in VEXAS syndrome: A retrospective study from an Italian multicentre cohort 16
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome 15
Totale 6.859
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.787
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.787
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202241 0 0 0 17 2 4 6 2 4 3 0 3
2022/2023305 75 58 15 3 8 36 29 38 19 10 9 5
2023/2024403 11 30 52 36 34 59 33 44 3 7 15 79
2024/20251.367 100 29 44 39 68 89 408 118 161 103 91 117
2025/20263.751 256 229 258 483 295 106 292 316 1.041 209 116 150
2026/2027933 139 212 195 387 0 0 0 0 0 0 0 0
Totale 6.859